Post-ERCP pancreatitis and its prevention

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 12, 2006, Pages 680-688

  Frank, Carl D ^a   Adler, Douglas G ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BILIRUBIN; CEFOTAXIME; CEFTAZIDIME; CONTRAST MEDIUM; CORTICOSTEROID; GABEXATE; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; IONIC CONTRAST MEDIUM; LIDOCAINE; LONG ACTING DRUG; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; NONIONIC CONTRAST MEDIUM; OCTREOTIDE; PLACEBO; SOMATOSTATIN; STEROID;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AGE DISTRIBUTION; BALLOON DILATATION; BILIRUBIN BLOOD LEVEL; CANNULATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GUIDE WIRE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MULTIPLE DRUG DOSE; NONHUMAN; OSMOLALITY; PANCREAS FUNCTION DISORDER; PANCREAS NECROSIS; PANCREAS PSEUDOCYST; PANCREATITIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SPHINCTEROTOMY; STENT; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VALIDATION PROCESS;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; PANCREATITIS; PATIENT SELECTION; RISK FACTORS;

EID: 34548479811     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0654     Document Type: Review

References (75)

1. Friedland S et al. (2002) Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 34: 483-488
2. Freeman ML et al. (2001) Risk factors for PEP: A prospective, multicenter study. Gastrointest Endosc 54: 425-434
3. Tsujino T et al. (2005) Risk factors for pancreatitis in patients with common bile duct stones managed by endoscopic papillary balloon dilation. Am J Gastroenterol 100: 38-42
4. Masci E et al. (2003) Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: A meta-analysis. Endoscopy 35: 830-834
5. Testoni PA et al. (1999) Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol 94: 1235-1241
6. Vandervoort J et al. (2002) Risk factors for complications after performance of ERCP. Gastrointest Endosc 56: 652-656
7. Masci E et al. (2001) Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 96: 417-423
8. Loperfido S et al. (1998) Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study. Gastrointest Endosc 48: 1-10
9. Barthet M et al. (2002) Complications of endoscopic sphincterotomy: results from a single tertiary referral center. Endoscopy 34: 991-997
10. Freeman ML et al. (1996) Complications of endoscopic biliary sphincterotomy. N Engl J Med 335: 909-918
11. Cohen S et al. (2002) National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy. Gastrointest Endosc 56: 803-809
12. Cotton PB et al. (1991) Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 37: 383-393
13. Singh P et al. (2004) Sphincter of Oddi manometry does not predispose to post-ERCP acute pancreatitis. Gastrointest Endosc 59: 499-505
14. Christoforidis E et al. (2002) PEP and hyperamylasemia: Patient-related and operative risk factors. Endoscopy 34: 286-292
15. Laugier R et al. (1991) Changes in pancreatic exocrine secretion with age: Pancreatic exocrine secretion does decrease in the elderly. Digestion 50: 202-211
16. Guelrud M et al. (1988) Effect of nifedipine on sphincter of Oddi motor activity: Studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 95: 1050-1055
17. Sand J and Nordback I (1993) Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 54: 105-111
18. Prat F et al. (2002) Nifedipine for prevention of PEP: A prospective, double-blind randomized study. Gastrointest Endosc 56: 202-208
19. Staritz M et al. (1985) Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut 26: 194-197
20. Staritz M et al. (1985) Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology 88: 1807-1811
21. Sudhindran S et al. (2001) Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 88: 1178-1182
22. Moreto M et al. (2003) Transdermal glyceryl trinitrate for prevention of PEP: A randomized double-blind trial. Gastrointest Endosc 57: 1-7
23. Schwartz JJ et al. (2004) The effect of lidocaine sprayed on the major duodenal papilla on the frequency of PEP. Gastrointest Endosc 59: 179-184
24. Hannigan BF et al. (1985) Hyperamylasemia after ERCP with ionic and non-ionic contrast media. Gastrointest Endosc 31: 109-110
25. Cunliffe WJ et al. (1987) A randomised, prospective study comparing two contrast media in ERCP. Endoscopy 19: 201-202
26. Johnson GK et al. (1995) A comparison of nonionic versus ionic contrast media: Results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 42: 312-316
27. Sherman S et al. (1994) PEP: Randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 40: 422-427
28. Raty S et al. (2001) Post-ERCP pancreatitis: Reduction by routine antibiotics. J Gastrointest Surg 5: 339-345
29. Niederau C et al. (1994) Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: Results of a randomized controlled clinical study. Gastrointest Endosc 40: 533-537
30. Vatn MH et al. (1980) A small dose of somatostatin inhibits the secretin stimulated secretion of bicarbonate, amylase, and chymotrypsin in man. J Endocrinol Invest 3: 279-282
31. Poon RT et al. (1999) Prophylactic effect of somatostatin on PEP: A randomized controlled trial. Gastrointest Endosc 49: 593-598
32. Poon RT et al. (2003) Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: A randomised controlled trial. Gut 52: 1768-1773
33. Arvanitidis D et al. (2004) Can somatostatin prevent PEP? Results of a randomized controlled trial. J Gastroenterol Hepatol 19: 278-282
34. Andriulli A et al. (2002) Gabexate or somatostatin administration before ERCP in patients at high risk for PEP: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56: 488-495
35. Andriulli A et al. (2003) Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: The evidence-based medicine derived from a meta-analysis study. JOP 4: 41-48
36. Kemmer TP et al. (1992) Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995). Aliment Pharmacol Ther 6: 41-50
37. Tulassay Z et al. (1998) Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 12: 1109-1112
38. Testoni PA et al. (2001) Octreotide 24-h prophylaxis in patients at high risk for PEP: Results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 15: 965-972
39. Manolakopoulos S et al. (2002) Octreotide versus hydrocortisone versus placebo in the prevention of PEP: A multicenter randomized controlled trial. Gastrointest Endosc 55: 470-475
40. Andriulli A et al. (2000) Pharmacologic treatment can prevent pancreatic injury after ERCP: A meta-analysis. Gastrointest Endosc 51: 1-7
41. Cavallini G and Frulloni L (2001) Somatostatin and octreotide in acute pancreatitis: The never-ending story. Dig Liver Dis 33: 192-201
42. Budzynska A et al. (2001) A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33: 766-772
43. De Palma GD and Catanzano C (1999) Use of corticosteriods in the prevention of PEP: Results of a controlled prospective study. Am J Gastroenterol 94: 982-985
44. Dumot JA et al. (1998) Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: A randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 93: 61-65
45. Sherman S et al. (2003) Does prophylactic administration of corticosteroid reduce the risk and severity of PEP: A randomized, prospective, multicenter study. Gastrointest Endosc 58: 23-29
46. Mosler P et al. (2005) Oral allopurinol does not prevent the frequency or the severity of PEP. Gastrointest Endosc 62: 245-250
47. Katsinelos P et al. (2005) High-dose allopurinol for prevention of PEP: a prospective randomized double-blind controlled trial. Gastrointest Endosc 61: 407-415
48. Katsinelos P et al. (2005) Intravenous N-acetylcysteine does not prevent PEP. Gastrointest Endosc 62: 105-111
49. Toulon P et al. (1991) Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man. Eur J Clin Invest 21: 303-309
50. Rabenstein T et al. (2002) Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 55: 476-483
51. Rabenstein T et al. (2004) Low-molecular-weight heparin does not prevent acute PEP. Gastrointest Endosc 59: 606-613
52. Van Laethem JL et al. (1998) Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut 43: 408-413
53. Deviere J et al. (2001) Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 120: 498-505
54. Dumot JA et al. (2001) A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 96: 2098-2102
55. Cavallini G et al. (1996) Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med 335: 919-923
56. Andriulli A et al. (2002) Gabexate or somatostatin administration before ERCP in patients at high risk for PEP: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56: 488-495
57. Fogel EL et al. (2002) Sphincter of Oddi dysfunction: Pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 34: 280-285
58. Harewood GC and Baron TH (2002) An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol 97: 1708-1712
59. Komatsu Y et al. (1998) Endoscopic papillary balloon dilation for the management of common bile duct stones: Experience of 226 cases. Endoscopy 30: 12-17
60. Bergman JJ et al. (1997) Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. Lancet 349: 1124-1149
61. Vlavianos P et al. (2003) Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones: A prospective randomised trial. Gut 52: 1165-1169
62. Disario JA et al. (2004) Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 127: 1291-1299
63. Smithline A et al. (1993) Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 39: 652-657
64. Sherman S et al. (1995) Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy induced pancreatitis? [abstract] Am J Gastroenterol 90: 1614
65. Tarnasky PR et al. (1998) Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 115: 1518-1524
66. Fazel A et al. (2003) Does a pancreatic duct stent prevent PEP? A prospective randomized study. Gastrointest Endosc 57: 291-294
67. Singh P et al. (2004) Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60: 544-550
68. Freeman ML and Guda NM (2004) Prevention of PEP: A comprehensive review. Gastrointest Endosc 59: 845-864
69. Goldberg E et al. (2005) Pancreatic-duct stent placement facilitates difficult common bile duct cannulation. Gastrointest Endosc 62: 592-596
70. Brackbill S et al. (2006) A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc 64: 45-52
71. Rashdan A et al. (2004) Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2: 322-329
72. Freeman ML et al. (2004) Pancreatic stent insertion: Consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 59: 8-14
73. Smith MT et al. (1996) Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 44: 268-275
74. Michopoulos S et al. (2003) First intention of the biliary tree cannulation by means of a sphincterotome and a hydrophilic guidewire is a low risk-high success rate ERCP method [abstract]. Gastrointest Endosc 57: AB201
75. Lella F et al. (2004) A simple way of avoiding PEP. Gastrointest Endosc 59: 830-834